Gilead Sciences Inc.

17 hours ago · fool.com

The company is having a great year.

2 days ago · businesswire.com

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:Wolfe Research Healthcare Conference on Tuesday, November 10 at 11:20 AM Eastern TimeUBS Global Biopharma Conference on Tuesday, November 17 at 10:00 AM Greenwich Mean TimeJefferies Global Healthcare Conference on Tuesday, November 17 at 2:30 PM Greenwich Mean TimeCiti's Global Healthcare Conference on Tuesday, December 1 at 11:00 A.

2 days ago · seekingalpha.com

Gilead Sciences, Inc. delivered its strongest growth in a decade, with Q3 revenues up 16% ex-Veklury and robust HIV franchise performance. GILD's HIV division remains dominant, but Biktarvy faces 2028 Medicare price controls, expected to reduce revenue by $1.5bn that year. Oncology and immunology franchises lag, with mixed M&A results and limited near-term growth outside HIV despite heavy investment.

2 days ago · zacks.com

Gilead tops Q3 earnings and revenue estimates as HIV sales, Trodelvy and Livdelzi drive growth, prompting an increase in 2026 product sales guidance.

2 days ago · zacks.com

Gilead Sciences, Inc. GILD raised its 2026 sales outlook following strong third-quarter growth while providing new details on a significant Biktarvy pricing headwind expected in 2028.

2 days ago · seekingalpha.com

Gilead Sciences faces valuation headwinds despite strong Q3 results and successful HIV, Trodelvy, and Yeztugo growth. Medicare pricing will reduce Biktarvy revenue by $1.5 billion annually starting in 2028, intensifying GILD's dependence on HIV. Q3 HIV growth was inflated by inventory build and a favorable channel mix, making it unsustainable for future quarters.

3 days ago · seekingalpha.com

Gilead Sciences had a strong Q3. Sales of Trodelvy, a Trop-2-directed antibody-drug conjugate approved for the treatment of breast cancer, were $506 million, up 41.7% YoY and 10.7% QoQ. On October 22, Gilead agreed to acquire PepStar's oral IL-23R inhibitor program, including HCXT-2001, for $1.275 billion upfront.

3 days ago · benzinga.com

Gilead Sciences, Inc. (NASDAQ:GILD) reported better-than-expected earnings for the third quarter on Thursday.

3 days ago · seekingalpha.com

Gilead Sciences, Inc. ( GILD ) Q3 2026 Earnings Call October 29, 2026 4:30 PM EDT Company Participants Jacquie Ross - Senior Vice President of Treasury & Investor Relations Daniel O'Day - Chairman & CEO Johanna Mercier - Chief Commercial & Corporate Affairs Officer Dietmar Berger - Chief Medical Officer Andrew Dickinson - Executive VP & CFO Cindy Perettie - Executive Vice President of Kite Conference Call Participants Umer Raffat - Evercore ISI Institutional Equities, Research Division Akash Tewari - Jefferies LLC, Research Division Mohit Bansal - Wells Fargo Securities, LLC, Research Division Brian Abrahams - RBC Capital Markets, Research Division Christopher Schott - JPMorgan Chase & Co, Research Division Michael Yee - UBS Investment Bank, Research Division Terence Flynn - Morgan Stanley, Research Division Daina Graybosch - Leerink Partners LLC, Research Division Louise Chen - Scotiabank Global Banking and Markets, Research Division Carter Gould - Cantor Fitzgerald & Co., Research Division Geoffrey Meacham - Citigroup Inc., Research Division Presentation Operator Good afternoon, everyone, and welcome to Gilead's Third Quarter 2026 Earnings Conference Call. My name is Rebekah, and I'll be today's host.

3 days ago · zacks.com

The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.